Puberteitsremmers (Dutch Wikipedia)

Analysis of information sources in references of the Wikipedia article "Puberteitsremmers" in Dutch language version.

refsWebsite

Global rank Dutch rank

4^th place

12^th place

2^nd place

8^th place

1books.google.com

3^rd place

43^rd place

1mayoclinic.org

1,610^th place

4,004^th place

1transgenderinfo.be

low place

6,922^nd place

1,864^th place

21^st place

low place

121^st place

1web.archive.org

1^st place

1^st place

low place

low place

7^th place

27^th place

bnnvara.nl

Nederlandse experts: bewijs genderbehandeling onvoldoende. Zembla. BNNVARA (26 oktober 2023). Gearchiveerd op 8 november 2023. Geraadpleegd op 8 november 2023.

books.google.com

Hemat, R.A.S.. Andropathy.

doi.org

(December 2016). Transgender youth: current concepts. Annals of Pediatric Endocrinology & Metabolism 21 (4): 185–192. PMID 28164070. PMC 5290172. DOI: 10.6065/apem.2016.21.4.185. “The primary risks of pubertal suppression in gender dysphoric youth treated with GnRH agonists include adverse effects on bone mineralization, compromised fertility, and unknown effects on brain development.”.
(2012). Clinical management of gender dysphoria in children and adolescents: the Dutch approach. Journal of Homosexuality 59 (3): 301–20. PMID 22455322. DOI: 10.1080/00918369.2012.653300.
(September 2017). Buying time or arresting development? The dilemma of administering hormone blockers in trans children and adolescents. Porto Biomedical Journal 2 (5): 153–156. PMID 32258611. PMC 6806792. DOI: 10.1016/j.pbj.2017.06.001.

endocrine.org

Longer treatment with puberty-delaying medication in transgender youth leads to lower bone mineral density. Endocrine Society (12 juni 2022). Geraadpleegd op 24 november 2023.

mayoclinic.org

Puberty blockers for transgender and gender-diverse youth. Mayo Clinic. Geraadpleegd op 24 november 2023.

nih.gov

ncbi.nlm.nih.gov

(December 2016). Transgender youth: current concepts. Annals of Pediatric Endocrinology & Metabolism 21 (4): 185–192. PMID 28164070. PMC 5290172. DOI: 10.6065/apem.2016.21.4.185. “The primary risks of pubertal suppression in gender dysphoric youth treated with GnRH agonists include adverse effects on bone mineralization, compromised fertility, and unknown effects on brain development.”.
(2012). Clinical management of gender dysphoria in children and adolescents: the Dutch approach. Journal of Homosexuality 59 (3): 301–20. PMID 22455322. DOI: 10.1080/00918369.2012.653300.
(September 2017). Buying time or arresting development? The dilemma of administering hormone blockers in trans children and adolescents. Porto Biomedical Journal 2 (5): 153–156. PMID 32258611. PMC 6806792. DOI: 10.1016/j.pbj.2017.06.001.

pubmed.ncbi.nlm.nih.gov

Bone mass in young adulthood following gonadotropin-releasing hormone analog treatment and cross-sex hormone treatment in adolescents with gender dysphoria. PubMed. Geraadpleegd op 24 november 2023.

nytimes.com

(en) Ghorayshi, Azeen, U.S. Study on Puberty Blockers Goes Unpublished Because of Politics, Doctor Says. The New York Times (23 oktober 2024). Geraadpleegd op 24 oktober 2024.

transgenderinfo.be

Puberteitsremmers, Transgenderinfo.be, Puberteitsremmers zijn dus geen “pauzeknop”, zoals soms wordt beweerd, maar een actieve stap in het gendertraject, die heel weloverwogen genomen dient te worden.

vrt.be

"Fel debat over puberteitsremmers en mannelijke/vrouwelijke hormonen: "Wat jullie doen, is een experiment op kinderen"", VRT NWS, 29 maart 2023. Geraadpleegd op 24 november 2023.

web.archive.org

Nederlandse experts: bewijs genderbehandeling onvoldoende. Zembla. BNNVARA (26 oktober 2023). Gearchiveerd op 8 november 2023. Geraadpleegd op 8 november 2023.